about
Obesity pharmacotherapy: current perspectives and future directionsUnraveling oxyntomodulin, GLP1's enigmatic brotherAnti-obesogenic and antidiabetic effects of plants and mushrooms.Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity.Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?Antipsychotic drugs and obesity.GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunitiesPharmaceutically controlled designer circuit for the treatment of the metabolic syndrome.Effects of exercise training on gut hormone levels after a single bout of exercise in middle-aged Japanese women.Comparative efficiency and safety of pharmacological approaches to the management of obesity.Obesity vaccines.Anti-obesity drugs: past, present and future.Do we need anti-obesity drugs?Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.Editors' pick 2009.Editorial for BJCP Special Obesity Edition.Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.Diet-induced obesity blunts the behavioural effects of ghrelin: studies in a mouse-progressive ratio task.Systemic and vascular inflammation in an in-vitro model of central obesity.Inhibitory Effects of 4-(4-Methylbenzamino)benzoate on Adipocyte Differentiation
P2860
Q26828559-CE3DA34F-A132-4E3E-92AD-EF459E90C123Q27001704-5EC64D9C-6DB1-411E-9BA9-ABADFE7C4708Q30241950-8AB880D4-41D2-4385-B1F2-4696DD37814DQ33613030-E1A3A250-5720-442C-A345-6DFDC49B8656Q34589770-081A2E66-DC5E-44D8-A910-4C2CF8A09F6EQ34648940-D84EA55D-917F-4744-8DC2-25F18435613EQ36153247-132424A0-5081-4E0B-88DD-3F3CCCADEA75Q36512376-962E62DC-DBBE-4B69-A9CC-445D3513B148Q36684108-6A81D455-C7D5-4ECE-9BA4-B9976BA07BE9Q36783891-FC549B7A-8600-4114-8F31-A4FF737C5D23Q36977740-BEA14B58-6040-42B1-A6B6-F359F411EBA6Q38036925-B18EE594-CF4F-46B1-8F18-8BD4B63D3B06Q38071006-6079BDA7-9FD0-48D1-A83C-4E0370F5E4C0Q39063782-4965C3FA-75A1-43E0-B9F8-D1350A99B76EQ41819403-29DB0E50-2CBE-4AAB-B323-0FFF586220F9Q42931506-E5552A0D-8E0B-4314-95B9-7CBD3954B67BQ46938116-D0B82ED7-2BDC-4BDB-9C95-6EB6C45B6D30Q48917304-3561A60C-A2D2-4576-8651-AE192646FE1AQ50041778-C9C0B635-6307-40A3-9F13-5484FFFC6165Q59111397-08721E9C-F206-4861-95FE-B15B8C52272F
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Obesity treatment: novel peripheral targets.
@ast
Obesity treatment: novel peripheral targets.
@en
type
label
Obesity treatment: novel peripheral targets.
@ast
Obesity treatment: novel peripheral targets.
@en
prefLabel
Obesity treatment: novel peripheral targets.
@ast
Obesity treatment: novel peripheral targets.
@en
P2093
P2860
P1476
Obesity treatment: novel peripheral targets.
@en
P2093
Benjamin C T Field
Owais B Chaudhri
Stephen R Bloom
P2860
P304
P356
10.1111/J.1365-2125.2009.03522.X
P407
P577
2009-12-01T00:00:00Z